Investors from abroad boost AnGes stocks by ¥3 billion
AnGes Inc., a spin-off from Osaka University, is making waves in the global biotechnology industry. The company, which has received significant attention worldwide, is preparing a Biologics License Application (BLA) with the U.S. Food and Drug Administration (FDA) for its gene therapy drug, Collategene®.
If approved, Collategene could become the world's first gene therapy for Critical Limb Threatening Ischemia (CLTI), potentially altering AnGes' valuation dramatically. The theme of AnGes' potential valuation significantly increasing with FDA approval is already being priced in by global investors, with foreign investors leading the charge.
AnGes' shares can be purchased from the UAE through IBKR, and the company's stock price has surpassed the ¥100 threshold, with buying momentum led primarily by foreign investors. The acquisitions of AveXis and Spark Therapeutics by Novartis and Roche, respectively, are frequently cited as relevant benchmarks for AnGes Inc.
The FDA approval application for Collategene® was presented by AnGes Inc. itself, and the drug has already completed U.S. clinical trials. Collategene has received Breakthrough Therapy Designation from the FDA, reflecting its potential to significantly improve health outcomes for patients with CLTI.
Ryuichi Morishita, a professor in the Department of Clinical Gene Therapy at Osaka University, has been instrumental in the development of Collategene. AnGes' growing presence in international headlines reflects a shift in market perception, with foreign investors moving first to position for the company's future potential.
Foreign investors are building positions in AnGes Inc., while Japanese investors have remained cautious. The market analysts observe that the theme of AnGes' potential valuation significantly increasing with FDA approval is hard to grasp in Japan, but it is being embraced by global biotech investors.
At present, AnGes has a market capitalization of approximately ¥34 billion, with analysts noting that global investors are already factoring in scenarios where FDA approval could propel this valuation into the hundreds of billions or beyond. International funds, including those from the United States and the UAE, are taking a positive view of AnGes Inc.
As momentum builds, AnGes stands at the threshold of redefining its role in the global biotechnology landscape. With the FDA's decision on Collategene's approval expected soon, the company is poised to make a significant impact in the treatment of CLTI and potentially revolutionise the gene therapy industry.
